Evidence map›Paper›PMID 42609473›Full record

ArticleFrontiers in immunology2026

Neoadjuvant anti-PD-1 monotherapy followed by watch-and-wait strategy in dMMR/MSI-H colorectal cancer: a multicenter real-world study.

Tengyu Li, Huaju Zhang, Pengyu Wei, Weiyu Feng, Huiliang Zhang, Shuai Ma, Quanbo Zhou, Shuang Zhao, Luyao Shao, Haifeng Sun and 16 more

Abstract readMulticenter Study
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

26 authors.

Tengyu Li *Department of Colorectal Surgery, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China.
Huaju Zhang *Department of Colorectal Surgery, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China.
Pengyu Wei *Department of General Surgery, Beijing Friendship Hospital, Capital Medical University, Beijing, China.
Weiyu Feng *Department of General Surgery, Affiliated Cancer Hospital of Zhengzhou University & Henan Cancer Hospital, Zhengzhou, China.
Huiliang Zhang *Department of General Surgery, Affiliated Cancer Hospital of Zhengzhou University & Henan Cancer Hospital, Zhengzhou, China.
Shuai MaDepartment of Colorectal Surgery, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China.
Quanbo ZhouDepartment of Colorectal Surgery, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China.
Shuang ZhaoDepartment of Internal Medicine, Affiliated Cancer Hospital of Zhengzhou University & Henan Cancer Hospital, Zhengzhou, China.
Luyao ShaoThe First Clinical School, Zhengzhou University, Zhengzhou, China.
Haifeng SunDepartment of Colorectal Surgery, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China.
Weipeng SunDepartment of Colorectal Surgery, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China.
Chao YangDepartment of Colorectal Surgery, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China.
Shengyun HuDepartment of Colorectal Surgery, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China.
Qingqing ZhangDepartment of Colorectal Surgery, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China.
Xiaofei DuanDepartment of Colorectal Surgery, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China.
Wei ZhangDepartment of Colorectal Surgery, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China.
Yangbang LianRadiology Department, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China.
Chang SuDepartment of Radiation Oncology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China.
Xuexiu ZhangDepartment of Gastroenterology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China.
Zhen LiDepartment of Colorectal Surgery, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China.
Guixian WangDepartment of Colorectal Surgery, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China.
Weitang YuanDepartment of Colorectal Surgery, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China.
Zhiyong ZhangDepartment of Colorectal Surgery, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China.
Xuan ZhangDepartment of Colorectal Surgery, Yunnan Cancer Hospital & The Third Affiliated Hospital of Kunming Medical University, Kunming, China.
Hongwei YaoDepartment of General Surgery, Beijing Friendship Hospital, Capital Medical University, Beijing, China.
Yugui LianDepartment of Colorectal Surgery, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Objective: This study aimed to assess the long-term results of the watch-and-wait (W&W) strategy in patients with clinical stage II/III mismatch repair deficiency (dMMR) or microsatellite instability-high (MSI-H) colorectal cancer (CRC) who received neoadjuvant anti-PD-1 monotherapy. Methods: This retrospective study enrolled stage II/III dMMR/MSI-H CRC patients from four Chinese tertiary hospitals between August 1, 2020 and February 28, 2025. All participants received neoadjuvant anti-PD-1 monotherapy followed by W&W approach. Results: A total of 49 patients managed with W&W strategy were enrolled, and all met the Conclusion: In this cohort, patients with dMMR/MSI-H CRC who met eCR after neoadjuvant anti-PD-1 monotherapy had excellent long-term outcomes when managed with W&W strategy. These findings support the potential utility of endoscopic assessment for selecting candidates for organ preservation, but prospective validation of standardized criteria is warranted.

Indexed as

Colorectal NeoplasmsDNA Mismatch RepairImmune Checkpoint InhibitorsMicrosatellite InstabilityNeoadjuvant TherapyProgrammed Cell Death 1 ReceptorWatchful WaitingAgedFemaleHumansMaleMiddle AgedNeoplasm StagingPathologic Complete ResponseRetrospective StudiesTreatment OutcomeImmune Checkpoint InhibitorsProgrammed Cell Death 1 Receptorcolorectal cancerdMMR/MSI-Hendoscopic complete responseneoadjuvant immunotherapywatch-and-wait

Identifiers

PMID42609473
PMCPMC13478261

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.